Deborah Jacobs, MD
Ophthalmology · Needham, MANPI 1689625709
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,275 of the $11,866 with a category attached, or 78.2%. Dompe US, Inc. accounts for 97.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $10,846 and has fallen 99.2% since, to $83 in 2025.
Across 16 payments — averaging $741.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$12K
- Biocryst Pharmaceuticals, Inc.$150
- Alcon$102
Across 5 payments — averaging $10,155 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coopervision Inc.$50K
- KOWA Company, LTD.$625
- Novartis$150
What the payments were for
- Consulting fees$9,27578%
- Speaking & faculty fees$1,57113%
- Food & beverage$1,0209%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 13 | $11,614 |
| Biocryst Pharmaceuticals, Inc. | 2 | $150 |
| Alcon | 1 | $102 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,866 in reported general payments places this provider in the 85th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LotemaxLoteprednol Etabonate | 13 | $5,232 |
| Loteprednol Etabonate | 18 | $3,313 |
| Cromolyn Sodium | 16 | $468 |
| Prednisolone Acetate | 12 | $320 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $255 |
| Gabapentin | 17 | $175 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 16 | $140 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Needham
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.